Epitomee Medical Ltd. logo

Epitomee Medical Ltd. (EPIT)

Market Closed
8 Dec, 15:14
TASE TASE
707. 50
ILA
-14.5
-2.01%
ILA
273.33M Market Cap
- P/E Ratio
0% Div Yield
19,914 Volume
0 Eps
722 ILA
Previous Close
Day Range
704.4 725.9
Year Range
661.2 1,160
Want to track EPIT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

EPIT closed today lower at 707.5 ILA, a decrease of 2.01% from yesterday's close, completing a monthly decrease of -3.81% or 28 ILA. Over the past 12 months, EPIT stock lost -23.98%.
EPIT is not paying dividends to its shareholders.
The last earnings report, released on Dec 27, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on TASE (ILA).

EPIT Chart

Similar

Medipower Overseas Public Co. Ltd.
658.2 ILA
-3.87%
Rekah Pharmaceutical Industry Ltd.
1,171 ILA
-0.09%
G.F.C Green Fields Capital Ltd.
1,355 ILA
0%
Bonus BioGroup Ltd.
26.8 ILA
+0.37%
BioLineRx Ltd.
1.7 ILA
-5.56%

Epitomee Medical Ltd. (EPIT) FAQ

What is the stock price today?

The current price is 707.50 ILA.

On which exchange is it traded?

Epitomee Medical Ltd. is listed on TASE.

What is its stock symbol?

The ticker symbol is EPIT.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 273.33M.

Has Epitomee Medical Ltd. ever had a stock split?

No, there has never been a stock split.

Epitomee Medical Ltd. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Dr. Radan Hashimshony Ph.D. CEO
TASE Exchange
IL0011825911 ISIN
Israel Country
42 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Epitomee Medical Ltd is a distinguished biomedical company specializing in the development and commercialization of innovative ingestible therapeutic devices on a global scale. Founded in 2005 and headquartered in Caesarea, Israel, the company has successfully positioned itself at the forefront of the biomedical field. A key highlight of its strategic efforts is the partnership with Nestlé Health Science S.A., aimed at advancing the development and distribution of a groundbreaking weight loss capsule. This collaboration underscores Epitomee Medical's commitment to combating obesity and related health issues through pioneering solutions.

Products and Services

Epitomee Medical Ltd offers a range of products and services designed to aid in weight management, reduce waist circumference, and mitigate cardiovascular risk factors. These offerings include:

  • Weight Management Capsule: An ingestible capsule developed by Epitomee Medical aimed at helping individuals achieve and maintain a healthy weight. This product leverages innovative mechanisms to facilitate weight loss in a safe and controlled manner.
  • Waist Circumference Reduction: In addition to weight management, the company's technology is geared towards the reduction of waist circumference, a critical factor in the assessment of obesity-related health risks.
  • Cardiovascular Risk Factors Reduction: The technology embodied in Epitomee Medical's products also contributes to the reduction of cardiovascular risk factors, offering a holistic approach to improving health and preventing disease.

Through its strategic partnership with Nestlé Health Science S.A., Epitomee Medical Ltd is not only enhancing the accessibility of its weight loss capsule but is also embarking on the path of developing new solutions that will further its mission of providing effective, accessible, and non-invasive health interventions.

Contact Information

Address: 19 Tarshish
Phone: 972 7 225 05992